During a major phase III trial, pembrolizumab combined with standard treatment kept cancer at bay for an average of 60 months ...

Report Ocean has published a new report on the Saudi Arabia Immuno-oncology Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report ...